Compare TG Therapeutics Inc (TGTX) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Tenet Healthcare Corporation — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Tenet Healthcare Corporation trades at $269.36 (market cap $20.86B). The key difference: Tenet Healthcare Corporation is far larger — about 2.4× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| TGTX | THC | |
|---|---|---|
Market Cap | $8.53B | $20.86B |
Sector | Health | Health |
52-Week High | $59.06 | $280.77 |
52-Week Low | $26.94 | $161.37 |
Enterprise Value | $8.74B | $31.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Tenet Healthcare (THC) trades at $259.06, down 2.26% today, with a bearish technical signal but strong fundamentals. The stock exhibits robust profitability with an 82.83% gross margin and 53.31% ROE, supported by three consecutive quarterly EPS beats. Recent news includes a $2.0 billion senior notes offering for refinancing and participation in the Wells Fargo Healthcare Conference.
Outlook remains positive given analyst consensus of 81.25% buy ratings and a $281.44 price target, implying 8.6% upside. Risks include debt refinancing execution and healthcare regulatory pressures, but earnings momentum and valuation multiples below industry averages present a compelling opportunity for value investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
